Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2523-2532

  Zhou, Xianxuan ^a   Li, Lingyun ^b   Linhardt, Robert J ^b   Liu, Jian ^c  

^a HEFEI UNIVERSITY OF TECHNOLOGY   (China)

^b Rensselaer Polytechnic Institute   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

antidote; coagulation; heparin; sulfatase; ULMWH

Indexed keywords

4 NITROCATECHOL; ANTIDOTE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; N ACETYLGLUCOSAMINE 6 SULFATASE;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME DEGRADATION; INHIBITION KINETICS; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTICOAGULANTS; ANTIDOTES; BINDING SITES; BLOTTING, WESTERN; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; ENZYME ACTIVATION; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR WEIGHT; PLASMIDS; POLYSACCHARIDES; SULFATASES; TIME FACTORS; TRANSFECTION;

CRICETULUS GRISEUS;

EID: 84877691282     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12169     Document Type: Article

References (36)

1. Feyerabend TB, Li J-P, Lindahl U, &, Rodewald H-R, (2006) Heparan sulfate C5-epimerase is essentail for heparin biosynthesis in mast cells. Nat Chem Biol 2, 195-196.
2. Rabenstein DL, (2002) Heparin and heparan sulfate: structure and function. Nat Prod Rep 19, 312-331. (Pubitemid 34656777)
3. Esko JD, &, Lindahl U, (2001) Molecular diversity of heparan sulfate. J Clin Invest 108, 169-173. (Pubitemid 32656238)
4. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, &, Lose EL, (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8, 365-393. (Pubitemid 23001002)
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, &, Zako M, (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777. (Pubitemid 29449208)
6. Sasisekharan R, &, Venkataraman G, (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4, 626-631.
7. Atha DH, Lormeau J-C, Petitou M, Rosenberg RD, &, Choay J, (1985) Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 24, 6723-6729. (Pubitemid 16207156)
8. Linhardt RJ, (2003) Heparin: structure and activity. J Med Chem 46, 2551-2564.
9. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa SA, Linhardt RJ, &, Liu J, (2011) Chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparin. Science 334, 498-501.
10. Beni S, Limtiaco JF, &, Larive CK, (2011) Analysis and characterization of heparin impurities. Anal Bioanal Chem 399, 527-539.
11. Bhaskar U, Sterner E, Hickey AM, Onishi A, Zhang F, Dordick JS, &, Linhardt RJ, (2012) Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol 93, 1-16.
12. Liu H, Zhang Z, &, Linhardt RJ, (2009) Lessons learned from the contamination of heparin. Nat Prod Rep 26, 313-321.
13. Haase M, Bellomo R, Rocktaeschel J, Ziemer S, Kiesewetter H, Morgera S, &, Neumayer HH, (2005) Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 20, 444-446. (Pubitemid 40276907)
14. Badger NO, (2010) Fondaparinux (Arixtra®), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia? J Pharm Pract 23, 235-238.
15. Boneu B, (2000) Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res 100, V113-V120.
16. Ghanny S, Warkentin TE, &, Crowther MA, (2012) Reversing anticoagulant therapy. Curr Drug Discov Technol 9, 143-149.
17. Lawrence R, Brown JR, Al-Mafraji K, Lamanna WC, Beitel JR, Boons GJ, Esko JD, &, Crawford BE, (2012) Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol 8, 197-204.
18. Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ, &, Guss JM, (1997) Structure of a human lysosomal sulfatase. Structure 5, 277-289. (Pubitemid 27158733)
19. Ghosh D, (2005) Three-dimensional structures of sulfatases. Methods Enzymol 400, 273-293. (Pubitemid 43054903)
20. Dierks T, Dickmanns A, Preusser-Kunze A, Schmidt B, Mariappan M, von Figura K, Ficner R, &, Rudolph MG, (2005) Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell 121, 541-552. (Pubitemid 40720008)
21. Litjens T, Bielicki J, Anson DS, Friderici K, Jones MZ, &, Hopwood JJ, (1997) Expression, purification and characterization of recombinant caprine N-acetylglucosamine-6-sulphatase. Biochem J 327, 89-94. (Pubitemid 27455465)
22. Xu S, Zhao L, Larsson A, Smeds E, Kusche-Gullberg M, &, Venge P, (2005) Purification of a 75 kDa protein from the organelle matrix of human neutrophils and identification as N-acetylglucosamine-6-sulphatase. Biochem J 387, 841-847. (Pubitemid 40685720)
23. Rosenberg R, &, Damu P, (1973) The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248, 6490-6505.
24. Domon B, &, Costello CE, (1988) A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj J 5, 397-409. (Pubitemid 19031141)
25. Turnbull J, Powell A, &, Guimond S, (2001) Heparan sulfate: decoding a dynamic multifunctional regulator. Trends Cell Biol 11, 75-82. (Pubitemid 32144754)
26. Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ, &, Liu J, (2010) Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem 285, 34240-34249.
27. Duncan MB, Chen J, Krise JP, &, Liu J, (2004) The biosynthesis of anticoagulant heparan sulphate by the heparan sulphate 3-O-sulphotransferase isoform 5. Biochim Biophys Acta 1671, 34-43. (Pubitemid 38327127)
28. Melnikova I, (2009) The anticoagulants market. Nat Rev Drug Discov 8, 353-354.
29. Petitou M, &, van Boeckel CAA, (2004) A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed 43, 3118-3133. (Pubitemid 39257600)
30. Robertson DA, Freeman C, Morris CP, &, Hopwood JJ, (1992) A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulfatases. Biochem J 288, 539-544.
31. Yang JH, Park JY, Kim SH, &, Yoo YJ, (2008) Shifting pH optimum of Bacillus circulans xylanase based on molecular modeling. J Biotechnol 133, 294-300. (Pubitemid 50013185)
32. Kailemia MJ, Li L, Ly M, Linhardt RJ, &, Amster J, (2012) Complete mass spectral characterization of a synthetic ultralow molecular weight heparin using collision induced dissociation. Anal Chem 84, 5475-5478.
33. Tissot B, Ceroni A, Powell AK, Morris HR, Yates EA, Turnbull JE, Gallagher JT, Dell A, &, Haslam SM, (2008) Software tool for the structural determination of glycosaminoglycans by mass spectrometry. Anal Chem 80, 9204-9212.
34. Pope M, Raska C, Thorp SC, &, Liu J, (2001) Analysis of heparan sulfate oligosaccharides by nanoelectrospray ionization mass spectrometry. Glycobiology 11, 505-513. (Pubitemid 32655244)
35. Karamanos NK, Vanky P, Tzanakakis GN, Tsegenidis T, &, Hjerpe A, (1997) Ion-pair high-performance liquid chromatography for determining disaccharide composition in heparin and heparan sulphate. J Chromatogr A 765, 169-179. (Pubitemid 27152227)
36. Zhang L, Lawrence R, Schwartz JJ, Bai X, Wei G, Esko JD, &, Rosenberg RD, (2001) The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate. J Biol Chem 276, 28806-28813.